Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2019-07-16 Regulatory Filings
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2019
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel to the SEC regarding a Registration Statement on Form S-1 for an initial public offering (IPO). It discusses confidential treatment requests, preliminary IPO price range, stock-based compensation expense, stock option grants, and detailed valuation methodologies for the company's common stock. The document is not a full financial report but rather a supplemental correspondence providing additional information to the SEC staff about the IPO registration. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is also not an announcement of a report but a regulatory filing related to the IPO process. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-07-16 English
Regulatory Filings 2019
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from a company and its legal counsel to the U.S. Securities and Exchange Commission regarding comments on a Draft Registration Statement on Form S-1. The letter discusses revisions to the registration statement, disclosures about drug candidates, clinical trials, risk factors, and other regulatory compliance matters related to the company's initial public offering process. The presence of the Form S-1 draft registration statement and the nature of the content clearly indicate this is related to a registration statement filing process, which is a regulatory filing. It is not an annual report, earnings release, or any other financial report type. The document is a regulatory correspondence and amendment submission to the SEC, fitting the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or certification but a substantive regulatory filing.
2019-07-05 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated July 5, 2019, for RAPT Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information about the company, the offering, risk factors, use of proceeds, management, financial data, and other disclosures typical of an S-1 filing. This is not an annual report, earnings release, or any other financial report type but a capital markets filing related to the company's IPO process. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-07-05 English
Regulatory Filings 2019
Regulatory Filings
2019-06-20 English
Regulatory Filings 2019
Regulatory Filings
2019-06-19 English
Capital/Financing Update 2019
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement submitted to the SEC on Form S-1 by RAPT Therapeutics, Inc. It is a registration statement under the Securities Act of 1933, which is used for initial public offerings (IPOs) or other securities offerings. The text includes detailed information typical of an S-1 filing, such as company overview, risk factors, use of proceeds, management discussion, and financial data. This is not an annual report, earnings release, or any other report type but a registration statement for a capital raising event. Therefore, the document fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities, including registration statements for public offerings.
2019-05-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.